An update on emerging drugs for Hodgkin lymphoma

Bibliography

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403
   PubMed Web of Science ®Google Scholar
• Ferlay J, Bray F, Pisani P. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No 5 version 20. IARC Press; Lyon: 2004
   Google Scholar
• Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29:1812-26
   PubMed Web of Science ®Google Scholar
• Goel A, Fan W, Patel AA, et al. Nodular lymphocyte predominant Hodgkin Lymphoma: biology, diagnosis and treatment. Clin Lymphoma Myeloma Leuk 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-52
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012;30:907-13
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791-9
   PubMed Web of Science ®Google Scholar
• Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol 2012;9:450-9
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Engert A. The role of autologous transplantation in Hodgkin lymphoma. Curr Hematol Malig Rep 2011;6:172-9
   PubMed Web of Science ®Google Scholar
• Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013;Sep;24(9):2430-4
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Muller H, Eichenauer DA, et al. Outcome and risk factors of Hodgkin Lymphoma patients who relapse or progress after autologous stem cell transplant. Leuk Lymphoma 2014. [Epub ahead of print]
   Google Scholar
• Boll B, Goergen H, Arndt N, et al. Relapsed Hodgkin Lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2013;10;31(35):4431-7
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of Brentuximab Vedotin for patients With relapsed or refractory Hodgkin's Lymphoma. J Clin Oncol 2012;30:2183-9
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310-17
   PubMed Web of Science ®Google Scholar
• Borchmann P, Treml JF, Hansen H, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003;102:3737-42
   PubMed Web of Science ®Google Scholar
• Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-9
   PubMed Web of Science ®Google Scholar
• Chen R, Smith SE, Ansell SM, et al. Three-year follow-up data and characterization of long-term remissions from an ongoing phase 2 study of Brentuximab Vedotin in patients with relapsed or refractory Hodgkin Lymphoma. Blood 2013;122:4382
   Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 2013;14:1348-56
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Plütschow A, Kreissl S, et al. Targeted Beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin Lymphoma: interim results of a randomized phase II study. Blood 2013;122:4344
   Google Scholar
• Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012;119:6379-81
   PubMed Web of Science ®Google Scholar
• Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013;98:611-14
   PubMed Web of Science ®Google Scholar
• Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011;12:1222-8
   PubMed Web of Science ®Google Scholar
• Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012;30:2197-203
   PubMed Web of Science ®Google Scholar
• Fanale MA, Westin JR, Fowler N, et al. A phase I study of Panobinostat in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory Classical Hodgkin Lymphoma (cHL). Blood 2013;122:252
   Google Scholar
• von Tresckow B, Skotnicki A, Lisukov I, et al. A phase III randomized, double blind, placebo controlled multi-center study of Panobinostat for maintenance of response in patients with Hodgkin Lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Blood 2013;21;122:4648
   Google Scholar
• Jundt F, Raetzel N, Muller C, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005;106:1801-7
   PubMed Web of Science ®Google Scholar
• Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85(5):320-4
   PubMed Web of Science ®Google Scholar
• Johnston P, Pinter-Brown L, Rogerio J, et al. Phase 2 study of everolimus for relapsed/refractory classical Hodgkin Lymphoma (cHL). Haematologica 2013;98:1-64
   PubMedGoogle Scholar
• Oki Y, Buglio D, Fanale M, et al. Phase I study of Panobinostat plus Everolimus in patients with relapsed or refractory Lymphoma. Clin Cancer Res 2013;19:6882-90
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Verstovsek S. Molecular pathways: jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res 2013;19:1933-40
   PubMed Web of Science ®Google Scholar
• Kuppers R. New insights in the biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2012;2012:328-34
   PubMedGoogle Scholar
• Diaz T, Navarro A, Ferrer G, et al. Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS One 2011;6:e18856
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Fanale M, et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 2012;30:4161-7
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-25
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Larson S, Trinkaus K, et al. A Phase 2 multicenter Study of continuous dose Lenalidomide in relapsed or refractory classical Hodgkin Lymphoma. ASH Annual Meeting Abstracts 2012 November 16 2012;120:1623
   Google Scholar
• Boll B, Borchmann P, Topp MS, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010;148:480-2
   PubMed Web of Science ®Google Scholar
• Böll B, Plütschow A, Fuchs M, et al. German hodgkin study group phase I trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older hodgkin lymphoma patients. Blood 2013;122:3054
   PubMed Web of Science ®Google Scholar
• Blum KA, Jung SH, Johnson JL, et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol 2010;21:2246-54
   PubMed Web of Science ®Google Scholar